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Abstract
We appraised the methodology, execution and quality of the five published
meta-analyses that are based on the five randomized controlled trials which
compared cardiotocography (CTG)+ST analysis to cardiotocography. The
meta-analyses contained errors, either created de novo in handling of original
data or from a failure to recognize essential differences among the randomized
controlled trials, particularly in their inclusion criteria and outcome parame-
ters. No meta-analysis contained complete and relevant data from all five ran-
domized controlled trials. We believe that one randomized controlled trial
excluded in two of the meta-analyses should have been included, whereas one
randomized controlled trial that was included in all meta-analyses, should have
been excluded. After correction of the uncovered errors and exclusion of the
randomized controlled trial that we deemed inappropriate, our new meta-
analysis showed that CTG+ST monitoring significantly reduces the fetal scalp
blood sampling usage (risk ratio 0.64; 95% confidence interval 0.47–0.88), total
operative delivery rate (0.93; 0.88–0.99) and metabolic acidosis rate (0.61;
0.41–0.91).
Abbreviations: BD, base deficit; BDblood, base deficit in blood; BDecf, base
deficit in extracellular fluid; CI, confidence interval; CS, cesarean section;
CTG+ST, cardiotocography combined with fetal ECG ST interval analysis;
CTG, cardiotocography; ECG, electro-cardiotocography; FBS, fetal scalp blood
sampling; FD, fetal distress; IPD, individual participant (patient) data; MA,
meta-analysis; ODFD, operative delivery for fetal distress; RCT, randomized
controlled trial; RR, risk ratio.
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Introduction
From 2012 to 2013, five meta-analyses (MAs) on the
value of cardiotocography (CTG) combined with fetal
ECG ST interval analysis (CTG+ST) have been published:
an updated Cochrane Review (1), one by a European
consortium involved in four of the five randomized con-
trolled trials (RCTs) performed on CTG+ST vs. CTG
alone (2) (denoted “European MA” in text and tables),
one by North American authors (3) (“American MA”),
one by a group in Stockholm, Sweden (4) (“Stockholm
MA”), and an individual participant data (IPD) MA by
the European consortium (5) (“IPD MA”). This mono-
graph focuses on the methodologies employed in the
MAs, the clinical outcomes considered, and the execution
and quality of each individual MA. New MAs were per-
formed in those events where we found critical differences
between the RCTs [see the accompanying Part I review
(6)], and when improper handling of RCT data or errors
were found in the five MAs.
Five meta-analyses
Five RCTs on CTG+ST vs. CTG alone were considered
for inclusion in the MAs: the “Plymouth RCT” published
by Westgate et al. in 1993 (7), the “Swedish RCT” by
Amer-Wahlin et al. in 2001 (8), the “Finnish RCT” by
Ojala et al. in 2006 (9), the “French RCT” by Vayssiere
et al. in 2007 (10), and the “Dutch RCT” by Westerhuis
et al. in 2010 (11). After the original articles, revised data
from the Swedish and Dutch RCTs were published in
2011 (12–14). Metabolic acidosis data from the Finnish
RCT have been revised (see below), but not data from
the Plymouth and French RCTs.
Statistical analyses
For supplementary statistical calculations, we used the
MEDCALC version 5.00.017 computer software (Med-
Calc Software, Mariakerke, Belgium). Two-sided statistics
were used with a p-value <0.05 considered significant. For
performing new MAs, we used the COCHRANE REVIEW
MANAGER version 5.2.7 computer software (The Cochra-
ne Collaboration, http://ims.cochrane.org/revman/down-
load). This program assesses heterogeneity with Tau2, I2
and chi-square (Cochrane Q) statistics, where heterogene-
ity is regarded as substantial if I2 exceeds 30% or the
chi-square test p-value is <0.10. An analysis showing low
heterogeneity can be presented with fixed-effect MA and
an analysis showing high heterogeneity with random-effect
MA; since the result is practically the same with the two
models at low heterogeneity, in the text and forest plots we
present the results as random-effect MAs.
Types of meta-analysis
The Cochrane, European, American and Stockholm MAs
used aggregated data (Table 1). The IPD MA analysed the
original raw data from participants in four of the five
RCTs. An IPD MA offers numerous statistical and clinical
advantages over an aggregate data MA (15). For example,
it increases the power to detect differential treatment
effects across individuals in RCTs and allows adjustment
for confounding factors in observational studies.
In the Cochrane, European and American MAs, the
random-effect and fixed-effect MA models were used as
appropriate, after testing for heterogeneity (Table 1).
However, there is no consensus in the literature as to the
ideal cut-off point for heterogeneity to be used for each
model. For example, Reid (16) recommends the fixed-
effect model at an I2 of ≤25% and the random-effect
model at ≥75%, but gives no certain recommendation for
values in between. Devane (17) gives a somewhat more
precise recommendation: at an I2 of 0–40%, heterogeneity
is not important; 30–60% represents moderate heteroge-
neity; 50–90% substantial heterogeneity; and 75–100%
considerable heterogeneity. Several other interpretations
can be found in the literature. The chi-square test has the
lowest power to detect heterogeneity and a p < 0.10 indi-
cates heterogeneity according to Devane (17). While the
I2 index quantifies the degree of heterogeneity in a MA,
the chi-square only informs us about the presence or
absence of heterogeneity (18). Devane (17) recommends
that in the case of statistical heterogeneity, the reasons for
this finding should be investigated and the statistical
approach appropriately modified.
In the MAs included in the present review, the cut-offs
for I2 heterogeneity varied from 30% (Cochrane MA) to
40% (American MA) and 50% (European MA) (Table 1).
In the American MA, when an I2 was ≥85%, the authors
chose to perform no MA, for example regarding fetal
scalp blood sampling (FBS). In the other MAs the ran-
dom-effect model was then used. The Tau2 cut-off was
set to >0 in the Cochrane and European MAs but was
Key Message
Published meta-analyses on studies comparing cardi-
otocography+ST analysis with cardiotocography only,
contained errors in handling of original data, unwar-
ranted inclusions/exclusions of trials, and variable
definitions of outcomes. A revised meta-analysis
showed reductions in fetal scalp blood sampling, total
operative delivery rate, and metabolic acidosis rate in
the CTG+ST arm.
2014 The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons on behalf of
Nordic Federation of Societies of Obstetrics and Gynecology. 93 (2014) 571–586572
Meta-analyses on the value of ST analysis P. Olofsson et al.
not defined in the American MA; the chi-square p-value
was <0.10 in the Cochrane and American MAs but not
calculated in the European MA.
Choosing the right model for MA is particularly impor-
tant for binary outcome variables because the fixed- and
random-effect models give different results. When heteroge-
neity is present, a confidence interval (CI) around the ran-
dom-effect pooled estimate is wider than the CI around a
fixed-effect pooled estimate (19). Thus, larger series are
required in the random-effect model to achieve the same
statistical power as in the fixed-effect model (20). This is
illustrated by the calculation of metabolic acidosis in the
European MA, showing an I2 of 33%: the random-effect
model showed a non-significant decrease of metabolic aci-
dosis in the CTG+ST group [risk ratio (RR) 0.72, 95% CI
0.43–1.19], but if the pre-defined cut-off for I2 heterogeneity
(50%) is used, the fixed-effect model will show a significant
reduction (RR 0.68, 95% CI 0.48–0.97) (Tables 1 and 6).
In summary, fixed- and random-effect models pose dif-
ferent questions. The random-effect model addresses the
question “what is the average intervention effect?” whereas
the fixed-effects model addresses the question “what is the
best estimate of the intervention effect?” (19). Since the
random-effect model estimates the underlying distribution
of effects and not a single effect, when the models do not
coincide it may not reflect the actual effect in the particular
population under study. When heterogeneity is present, the
random-effect MA will award more weight to smaller trials
than such studies would receive in a fixed-effect MA. Con-
sequently, if the results of smaller trials are consistently dif-
ferent from those of larger ones, which is the case with the
Finnish and French RCTs, the direction of the outcomes in
the entire MA can be shifted. A random-effect MA as a rule
gives a more conservative 95% CI.
Before presenting our evaluation of the individual
MAs, it is important to recognize that random-effect
analysis is not a solution for the difficulties inherent in
translating the results of a MA to the realities of daily
clinical practice. The Cochrane Handbook (19) states that
the choice between a fixed-effect and a random-effect
MA should never be made on the basis of a statistical test
for heterogeneity. As will become evident, this recom-
mendation was not uniformly applied to the MAs under
consideration.
Inclusion and exclusion of RCTs and their
relevant data in the meta-analyses
The Cochrane Review included all five RCTs in its MA
and cited the revised versions of the Swedish and Dutch
Table 1. Details of five meta-analyses (MAs) based on five randomized controlled trials (RCTs) on the value of cardiotocography (CTG) combined
with fetal ECG ST interval analysis (CTG+ST) for fetal surveillance in labor.
Meta-analysis
Cochrane review
Neilson (2012)
European MA
Becker et al. (2012)
American MA
Potti & Berghella
(2012)
Stockholm MA
Salmelin et al.
(2013)
IPD MA
Schuit et al. (2013)
Type of meta-
analysis
Aggregate Aggregate Aggregate Aggregate Individual participant
data
Data collection 5 RCTs, principal
authors of Swedish
and French RCTs
contacted for missing
data
5 RCTs, principal
authors of Swedish,
Finnish, French and
Dutch RCTs among
authors to European
and IPD MAs
5 RCTs, only data
used in original
articles are used
4 RCTs, only data
used in original
articles are used
4 RCTs, IPD provided
by principal
investigators: all
randomized cases
from Swedish and
French RCTs included,
from Finnish RCT 11
exclusions, from Dutch
RCT 14 exclusions
Measures of
treatment
effect
RR with 95% CI (fixed-/
random-effect model
as appropriate);
fixed-effect when no
heterogeneity
RR with 95% CI
(fixed-/random-
effect model as
appropriate); fixed
effect when no
heterogeneity
RR with 95% CI
(fixed-/random-
effect models as
appropriate); fixed-
effect when no
heterogeneity
RR with 95%CI;
consistently
random-effect,
although tests
for heterogeneity
were performed
RR with an RR <1
indicating treatment
benefit; random-effect
log-binomial model;
imputation of missing
data
Assessment of
heterogeneity
(figures indicate
substantial
heterogeneity)
Tau2 (>0), I2 (>30%),
chi-square for
heterogeneity
(p < 0.10)
Tau2 (>0), I2 (>50%) I2 (40–84%, if ≥85%
no MA), chi-square
for heterogeneity
(p < 0.10)
Performed, but
random-effects
MA consistently
used
I2 (0% indicating no
heterogeneity, 25%
low, 50% moderate,
75% high)
IPD, individual participant data; RR, risk ratio.
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RCTs (12,14), but it did not include the revised Swedish
data in the final analysis (Table 2). The Cochrane MA
chose to use base deficit (BD) in blood (BDblood) and not
BD in extracellular fluid (BDecf) for calculation of meta-
bolic acidosis, but BDblood metabolic acidosis was
reported only in the Finnish and Dutch RCTs – the
Plymouth, Swedish and French RCTs reported BDecf met-
abolic acidosis. Consequently, the Cochrane MA is a
mixture of two different ways to calculate BD and its
metabolic acidosis result is therefore not uniform, because
the different BD calculation algorithms have a large
impact on the incidence of metabolic acidosis [see below
and the accompanying Part I review (6)].
The European MA authors also included all five RCTs
in their analysis (Table 2). However, the Swedish RCT
data presented are from the original so-called modified
intent-to-treat analysis from 2001 (n = 4966) (8), not the
revised data from the so-called standardized intention-to-
treat from 2011 (n = 5049) (12). The European consor-
tium authors aimed to calculate metabolic acidosis with
BDecf data and converted the Finnish BDblood data to
BDecf data to be comparable with the other RCTs, but
they included cases with missing blood gases in the
denominators when calculating the metabolic acidosis
rates (6/733 vs. 4/739 instead of 6/714 vs. 4/722). Thus,
the European MA did not contain all relevant data from
Table 2. Details of RCTs included/excluded in the MAs, with special reference to calculation of neonatal metabolic acidosis.
Meta-analysis RCT
Cochrane MAa
Neilson (2012)
European MAb
Becker et al.
(2012)
American MAc
Potti & Berghella
(2012)
Stockholm MAd
Salmelin et al.
(2013)
IPD MAe
Schuit et al.
(2013)
Plymouth RCT
(Westgate et al.,
1993)
Included with
BDecf data for
metabolic acidosis
Included Included Excluded because of
non-computerized
ST analysis method
Excluded because of
non-computerized
ST analysis method
and no access to
IPD
Swedish RCT original
data (Amer-Wahlin
et al., 2001)
Included with
BDecf data for
metabolic acidosis
Included but incorrect
data used in MA
Included Included IPD included
Swedish RCT revised
data on metabolic
acidosis (Amer-Wahlin
et al., 2011)
Article cited but
revised data not
used in MA
Article cited but
revised data not
used in MA
Not included,
not cited
Included IPD included
Finnish RCT original
data (Ojala et al.,
2006)
Included with
BDblood data for
metabolic acidosis
Included Included Included IPD included
Awareness of different
calculation of
metabolic acidosis in
Finnish RCT?
No Yes, but wrong
denominators
included in MA
No, included BDblood
in metabolic acidosis
calculation
Yes, but included
BDblood in metabolic
acidosis calculation
Yes, included Finnish
BDecf data in
metabolic acidosis
calculation
French RCT (Vayssiere
et al., 2007)
Included with
BDecf data for
metabolic acidosis
Included Included Included IPD included
Dutch RCT original data
(Westerhuis et al.,
2010)
Included Included Included Included IPD included
Dutch RCT revised data
on metabolic acidosis
BDecf, pH <7.05, pH
<7.00 (Westerhuis
et al., 2011)
Included with
revised BDblood
data for metabolic
acidosis
Included, correct data
used for metabolic
acidosis
Included, correct data
used for metabolic
acidosis but revised
article not cited
Included, correct data
used for metabolic
acidosis
IPD included, correct
data used for
metabolic acidosis
Number of cases
included
15 338 15 352 (≤15 338
included in analyses)
15 303 12 904 12 987
BDblood, base deficit in blood; BDecf, base deficit in extracellular fluid.
aThe Cochrane review aimed to analyse metabolic acidosis with BDblood.
bThe European MA aimed to analyse metabolic acidosis with BDecf.
cThe American MA did not define the fetal compartment for calculation of BD.
dThe Stockholm MA did not decide to calculate BDecf and BDblood metabolic acidosis separately.
eThe IPD MA aimed to analyse metabolic acidosis with both BDecf and BDblood without mixing of data.
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the five RCTs. In a second sequence of the European MA,
“sensitivity analyses” excluded the Plymouth RCT, as it
used visual analysis of absolute T/QRS ratios and because
biphasic ST interval changes were not yet part of the
method (but this is not correct, see below).
The American MA included all five RCTs but with the
original metabolic acidosis data instead of the revised
data from the Swedish trial group (Table 2). Moreover,
the use of BDblood instead of BDecf to calculate metabolic
acidosis in the Finnish RCT was not taken into account
(see below). The Stockholm MA also disregarded the fact
that the Finnish RCT reported BDblood data. Thus, the
American and Stockholm MAs on metabolic acidosis
were mixtures of BDecf and BDblood data (Table 2). The
IPD MA aimed to analyse metabolic acidosis with both
BDecf and BDblood calculations of metabolic acidosis and
the concepts were not mixed together.
The Stockholm and IPD MAs excluded the Plymouth
RCT because of the non-computerized ST analysis meth-
odology and, in the case of the IPD MA, because biphasic
ST interval changes were not included in the ST analysis
guidelines (Table 2). The latter claim is not entirely cor-
rect because negative T wave and ST interval depression
with positive T waves were included in the Plymouth
RCT management protocol [see Westgate et al., 1993 (7),
Table II)]. In a response to a Letter to the Editor of the
American Journal of Obstetrics and Gynecology by Rosen
(21), the principal IPD MA author admitted that biphasic
ST changes were incorporated in the Plymouth RCT
management protocol, and that another reason for not
including the Plymouth data was that they had no access
to the IPD (22). The Plymouth RCT authors were con-
tacted but could not provide the required data. This has
affected the results of the IPD MA (and the Stockholm
MA), since the Plymouth RCT contributed considerable
weight, 16.2–17.0%, to the analyses of metabolic acidosis
in those MAs that included it (1–3).
The IPD MA authors make an assertion that all RCTs
had the same inclusion criteria, making them only
“slightly different”. However, the French RCT only
included women with abnormal CTG in labor with or
without meconium-stained amniotic fluid, but excluded
normal CTG cases (10), criteria that in many cases are
violations of the ST analysis clinical guidelines and rec-
ommendations (23,24). This fact alone should have inval-
idated the French RCT from inclusion not only in the
IPD MA but also in the other MAs [for details, see the
accompanying Part I review (6)].
Handling of missing data
Several of the variables evaluated in the MAs were not
reported in the original RCTs, and we could not perform
post hoc analyses of these variables. The Cochrane Review
author contacted the authors of the original reports to
provide further data. Representatives from all RCTs
except the Plymouth RCT were co-authors of the Euro-
pean MA and IPD MA and could have provided missing
data; the American and Stockholm MAs were performed
without contributions from authors of the included
RCTs.
Fetal scalp blood sampling: discrepancies in the
meta-analyses
In all five RCTs, FBS was an adjunct diagnostic tool in
both the CTG+ST group and CTG alone group. However,
it is unclear why the Swedish RCT data were not available
for the IPD MA (Table 3). In the Cochrane Review the
rates of FBS in the Dutch RCT were tabulated as an out-
come variable, but these data were not included in the
MA. The Cochrane MA reported an RR of 0.61 (95% CI
0.41–0.91), but if the Dutch RCT data (302/2827 vs. 578/
2840) are included, this results in an RR of 0.59 (95% CI
0.55–0.65) (788/7697 vs.1316/7641). Thus, inclusion of
the large Dutch RCT series results in a narrower and
more robust CI but no important change in RR. The
American MA did not analyse FBS because of their calcu-
lation of high heterogeneity among studies.
A new meta-analysis of fetal scalp blood
sampling
All four MAs that evaluated FBS usage showed significant
reductions in the CTG+ST group, ranging from 39 to
51%, but in the Cochrane Review and the IPD MA the
data were not complete (Table 3). As discussed in the
accompanying Part I review (6) and elsewhere in the
present review, the French RCT should not be pooled in
an MA with the other RCTs because of methodological
discrepancies. Our MA including the four other RCTs
showed a significant reduction in FBS usage by 36%
in the CTG+ST group (RR 0.64, 95% CI 0.47–0.88)
(Figure 1, Table 4).
Operative delivery: discrepancies in the meta-
analyses
It is not possible to determine the total cesarean and
operative vaginal delivery rates in the Plymouth and
French RCTs. Imputed data for the Cochrane Review
were provided by the original RCT authors. For reasons
that are unclear, data on total operative vaginal delivery
rate from the Dutch RCT were not included in the Coch-
rane Review (Table 3). The Cochrane MA showed an RR
of 0.89 (95% CI 0.81–0.98), which after inclusion of
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Dutch RCT data (384/2827 vs. 431/2840) becomes RR
0.89 (95% CI 0.83–0.96) (1044/7697 vs. 1162/7641); thus
adding Dutch trial data slightly narrowed the CI.
The European consortium performed a “sensitivity
analysis” that excluded the Plymouth RCT, based on its
different ST analysis methodology. The sensitivity analysis
resulted in a change of result from a total operative deliv-
ery RR of 0.94 (95% CI 0.88–0.99) (Table 3) to 0.95
(95% CI 0.89–1.00). While this change in RR is insignifi-
cant, it does result in a CI that includes unity.
The most detailed trial data were presented in the IPD
MA by Schuit et al. (5). We found addition errors in this
MA, as pointed out in Tables 3 and 6. For example, when
the numbers of interventions for “fetal distress” and “fail-
ure to progress” are added, which, if not otherwise stated,
are expected to include the total number of cesarean sec-
tions (CS) and instrumental vaginal deliveries, respec-
tively, we found summary discrepancies in all figures of
the individual RCTs [for details, see Table 3 in Schuit
et al. (5)]. To illustrate, in the Swedish RCT the number
of CSs for fetal distress was 194 and for failure to progress
217, resulting in 411 CSs. The number reported is 447, i.e.
an excess of 36 cases. Similar discrepancies are noted for
instrumental vaginal delivery (ventouse or forceps) and
operative delivery (CS plus instrumental vaginal). It is
unclear what the excess cases represent if they are unclassi-
fied operative deliveries or errors.
New meta-analyses of operative delivery
As shown in Table 3, the MAs varied in their analysis of
operative delivery rates. All MAs included the French
RCT, but for previously stated reasons we excluded the
French trial and performed new MAs according to the
following hierarchy of analyses and sub-analyses:
• total CS rate, with sub-analysis of CS for fetal distress
(FD) among all CSs.
• total instrumental (operative) vaginal delivery rate,
with sub-analysis of instrumental delivery for FD among
all instrumental vaginal deliveries.
• total operative delivery rate (including CS and opera-
tive vaginal deliveries), with sub-analysis of operative
delivery for fetal distress (ODFD) among total operative
deliveries.
Details of the hierarchy of cases included in these MAs
are shown in Table 5 and the results of the MAs are
summarized in Table 4. The forest plot in Figure 2
Figure 1. Forest plot and details of an aggregate meta-analysis of the usage of fetal scalp blood sampling in labor.
Table 4. Aggregate meta-analyses comparing CTG+ST vs. CTG alone. The Plymouth, Swedish, Finnish and Dutch RCTs were included in the
meta-analyses, calculated with the COCHRANE REVIEW MANAGER statistical computer software version 5.2.7.
Outcome
No. of
participants
RR (95% CI)
fixed-effect
RR (95% CI)
random-effect I2
Chi-square
p-value
Fetal scalp blood sampling 14 539 0.63 (0.58–0.69) 0.64 (0.47–0.88) 90% <0.00001
Total cesarean sectiona 14 539 1.00 (0.91–1.10) 1.00 (0.91–1.11) 10% 0.34
Fetal distress among all cesarean sections 1546 0.97 (0.77–1.22) 0.84 (0.54–1.32) 66% 0.03
Total operative vaginal delivery 14 539 0.88 (0.81–0.95) 0.88 (0.81–0.95) 0% 0.97
Fetal distress among all operative vaginal
deliveries
1977 0.95 (0.85–1.06) 0.90 (0.72–1.12) 73% 0.01
Total operative delivery 14 539 0.93 (0.88–0.99) 0.93 (0.88–0.99) 0% 0.44
Fetal distress among all operative deliveries 3523 0.95 (0.86–1.04) 0.87 (0.68–1.10) 83% 0.0004
aCesarean section data from the Plymouth RCT (7) were obtained from the Cochrane Review (1).
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demonstrates a significant 7% reduction in total operative
delivery rate in the CTG+ST group (RR 0.93, 95% CI
0.88–0.99), mainly as a result of a significant 12%
decrease in instrumental vaginal delivery rate (RR 0.88,
95% CI 0.81–0.95) (Table 4). The total CS rate was not
affected. A minority of operative deliveries were per-
formed for FD, 27–39% in the CTG+ST group and 28–
41% in the CTG group (Table 5); sub-analyses showed
no significant differences in ODFD among either CSs or
instrumental vaginal deliveries (Table 4).
Metabolic acidosis: discrepancies in the
meta-analyses
As mentioned above, in the Cochrane, American and
Stockholm MAs, metabolic acidosis rates were a mixture
of calculations using BDecf and BDblood (Tables 2 and 6).
As in the Finnish RCT, it appears that the difference
between BDecf and BDblood metabolic acidosis calculations
was not considered, despite important differences in
methodology. According to a personal communication
between Welin and colleagues (25) and the principal
Finnish author, Dr. Ojala, the figures of metabolic acido-
sis in extracellular fluid were 6/714 (0.8%) in the
CTG+ST group and 4/722 (0.6%) in the CTG group
(25,26). To the best of our knowledge, these data have
not been published by the Finnish RCT authors.
The Cochrane Review aimed to analyse BDblood meta-
bolic acidosis and included the revised Dutch RCT
BDblood data (14) in the MA (Tables 2 and 6). The Dutch
RCT rates for metabolic acidosis in the CTG+ST group
vs. the CTG group, based on those calculated for blood,
were 41/2827 (1.45%) vs. 66/2840 (2.32%), respectively;
when calculations for metabolic acidosis in extracellular
fluid were applied, the subsequent rates were much smal-
ler, 19/2827 (0.67%) vs. 27/2840 (0.95%) (14). This is a
crucial point in MAs because the incidence of BD
>12.0 mmol/L may differ by a factor of 4 between
BDblood and BDecf calculations (27,28). This difference in
definition of an essential RCT outcome variable would be
considered a high risk bias according to the Cochrane
Handbook for Systematic Reviews of Interventions (19).
The data in the Cochrane Review stated to represent
rates of metabolic acidosis in the Swedish RCT, 12/2159
(0.56%, CTG+ST) vs. 24/2079 (1.15%, CTG alone), and
in the Stockholm MA, 12/2519 (0.48%, CTG+ST) vs. 24/
2447 (0.98%, CTG alone), are not those published by the
Swedish RCT authors. The actual rates of metabolic aci-
dosis in the Swedish RCT were 15/2159 (CTG+ST) vs.
31/2079 (CTG alone) in the original article (8) and 18/
2565 (0.70%, CTG+ST) vs. 35/2484 (1.41%, CTG alone)
in the revised article including imputed data (12).
As discussed above, there were six cases of metabolic
acidosis in the CTG+ST analysis group and four in the
CTG alone group in the Finnish RCT. Altogether 1472
cases were randomized in the RCT, with blood gas data
available in 1436. However, the European consortium
MA included all 1472 randomized cases as denominator
Table 5. Details and hierarchy of cases included in the meta-analyses of operative delivery (n = 14 539).
Meta-analysis
CTG+ST analysis
n = 7298
. . . of whom had operation
for fetal distress
CTG alone
n = 7241
. . . of whom had operation
for fetal distress
Cesarean section 777 (10.6%) 208 (26.8%) 769 (10.6%) 212 (27.6%)
Operative vaginal delivery 927 (12.7%) 358 (38.6%) 1050 (14.5%) 426 (40.6%)
Total operative delivery 1704 (23.3%) 566 (33.2%) 1819 (25.1%) 638 (35.1%)
Figure 2. Meta-analysis of total operative delivery (sum of cesarean sections and instrumental vaginal deliveries). Data on total cesarean section
from the Plymouth randomized controlled trial (Westgate et al., 1993) (7) were obtained from the Cochrane Review (1).
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when calculating metabolic acidosis rate rather than only
those 1436 in which cord blood gas data were available.
A similar error in data extraction was made from the
Swedish RCT, in which the cases with missing cord blood
gas data were included in the denominator. Further, the
number of cases with metabolic acidosis (12 in the
CTG+ST group and 24 in the CTG group) are not those
published in the Swedish RCT.
The American MA authors have, like those of the
Stockholm MA, also used the Finnish RCT BDblood values
rather than the BDecf values (Tables 2 and 6). Metabolic
acidosis data from the original (8) but not from the
revised (12) Swedish RCT article were included in the
American MA, although the revised data from the Dutch
RCT (14) were used. After imputation of missing data in
the IPD MA, one additional case of metabolic acidosis
using BDecf occurred in the Swedish RCT data file and
six in the French RCT data file, whereas in the Finnish
and Dutch RCT files there were no additions (Table 6).
The Swedish authors themselves performed an imputation
data analysis that resulted in 53 cases (12), compared
with the 54 cases in the IPD MA. This discrepancy
remains unexplained.
The French RCT reported the number of cases with
BDecf >12.0 mmol/L. As discussed in the accompanying
Part I review (6), as many as 15% of the cases in the RCT
had a BDecf value >12.0 mmol/L and of these, only 15%
fulfilled the cord blood sample validation criterion of an
arteriovenous pCO2 gradient >0.5 kPa defined in the study
protocol. This confirms that the French RCT included cases
at extraordinary high risk for fetal compromise, and indi-
cates a poor quality of cord blood samples.
The IPD MA was the only one to evaluate metabolic
acidosis with both BDecf and BDblood >12.0 mmol/L
(Table 6). BDblood >12.0 mmol/L data were presented
from the Finnish and Dutch RCTs but not from the
Swedish and French RCTs. It is unclear why this approach
was undertaken. The BDblood calculation algorithm was
not reported in the IPD MA article (or in the Finnish and
Dutch RCTs), but with access to original individual
participant pH and pCO2 data from each trial there is no
risk of discrepant post hoc calculations. The concept of an
IPD MA is that all individual RCT data shoould be han-
dled as if the MA was a single large multicenter RCT. This
is important, since comparing different BD algorithms,
the incidence of BDblood >12.0 mmol/L may differ by
more than 150% (2.5 times) (28). Different algorithms in
the Finnish RCT and the IPD MA to calculate BDblood
might explain why the original 17 cases of BDblood
>12.0 mmol/L in the Finnish RCT increased to 23 when
included in the IPD MA. Such large discrepancies between
blood gas analyzers are clinically important: at low
and moderately high BDblood values the inter-analyzer
difference might be 3–4 mmol/L and at high values up to
8–9 mmol/L (28).
New meta-analysis of neonatal metabolic acidosis
Our judgement is that the relevant rates of metabolic aci-
dosis in extracellular fluid should be represented by data
published in the original Plymouth and French RCT arti-
cles (7,10), the Swedish and Dutch revised data articles
(12,14), and data presented by Welin and coworkers after
communication with the principal Finnish RCT author
(25). Figure 3 shows a forest plot with inclusion of these
data from the Plymouth, Swedish, Finnish and Dutch
RCTs: fetal surveillance with CTG+ST analysis resulted in
a significant 39% reduction in metabolic acidosis com-
pared with surveillance with CTG alone (RR 0.61, 95%
CI 0.41–0.91).
Admission to the neonatal intensive care unit:
discrepancies in the meta-analyses
Admissions to the neonatal intensive care unit (Table 6)
were reported in all five RCTs. Fewer cases were included
Figure 3. Meta-analysis of neonatal metabolic acidosis. Data from the Finnish randomized controlled trial (9) are from Dr. Ojala’s personal
communication with Welin et al. (25), the Swedish (Amer-Wahlin et al., 2011) and Dutch (Westerhuis et al., 2011) data are from the revised
articles (12,14), while the Plymouth data (Westgate et al., 1993) are from the original article (7).
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in the IPD MA in the original Finnish RCT (n = 49 vs.
52) and French RCT (n = 10 vs. 11). Since retrieval of
missing data cannot create fewer cases, these differences
raise concern about bias or incorrect summations.
Neonatal encephalopathy: discrepancies in the
meta-analyses
The Stockholm MA authors stated that encephalopathy
was reported in all four of the RCTs that were included.
This is incorrect, since the occurrence of neonatal seizures
but not encephalopathy was reported in the French RCT
(Table 6). Furthermore, they stated that hypoxic ischemic
encephalopathy (HIE) was explicitly reported only in the
Dutch RCT, but the Swedish RCT reported figures for
HIE stage ≥1 and ≥2 separately. Both RCTs classified neo-
natal encephalopathy according to the criteria of Sarnat &
Sarnat (29). The other RCTs either failed to report this
outcome or failed to define its stage.
In the Cochrane, American and Stockholm MAs, neona-
tal encephalopathy represents a mixture of Sarnat & Sarnat
encephalopathy stage ≥1 (Swedish RCT), stage ≥2 (Swed-
ish, Dutch RCTs), unknown stage (Finnish RCT) and sei-
zures (French RCT) (Table 6). The European MA reported
data on neonatal encephalopathy stage ≥2 from three RCTs
but, as mentioned above, such data were provided in only
the Swedish and Dutch RCT articles. We determined that
the third study included in the European MA was the Finn-
ish RCT, in which encephalopathy was not defined. In this
trial one neonate in the CTG group was diagnosed with
encephalopathy but two had seizures, which might be in
conflict with the Sarnat & Sarnat classification, since sei-
zures usually represent Sarnat & Sarnat stage ≥2 encepha-
lopathy. The Sarnat & Sarnat encephalopathy classification
cannot be performed retrospectively by MA authors and
for this reason we could not evaluate the correctness of the
results reported in the European MA.
The IPD MA included seven cases of (undefined) HIE
from the Swedish RCT. The Swedish authors themselves
reported 11 cases of HIE stage ≥1, among whom three
cases were stage 2. Similar discrepancies could be applied
to the calculations in the Finnish and Dutch RCTs: in the
former, the RCT authors reported one case of encepha-
lopathy and two cases of seizures and the IPD MA
authors included one case of HIE; in the latter, the RCT
authors reported four cases of HIE stage ≥2 and the IPD
MA authors included two cases. Such differences between
the original RCTs and the IPD MA remain unexplained.
A new meta-analysis of neonatal encephalopathy
A comparison of Sarnat & Sarnat classified neonatal
encephalopathy should only include data from the Swed-
ish and Dutch RCTs. Our MA including stage ≥2 showed
no effect of CTG+ST monitoring (RR 0.75, 95% CI 0.04–
15.69) on the prevalence of this complication (Figure 4).
Neonatal intubation: discrepancies in the meta-
analyses
The need for neonatal intubation was reported only in
the Finnish RCT (n = 16), but data from the French and
Dutch RCTs were supplemented in the IPD MA
(Table 6). However, in the IPD MA only 12 cases from
the Finnish RCT were included. Such a difference
between the original trial and the IPD MA remains
unexplained.
Perinatal mortality: discrepancies in the meta-
analyses
Data on perinatal death (Table 6) were reported in all
RCT articles except in the Plymouth trial. The Cochrane
Review author contacted the authors of the original
reports for missing data and the two deaths in the Plym-
outh trial (both in the CTG+ST group) were included in
the MA. These deaths were also reported by Jennifer
Westgate in her thesis (30). The American MA included
the two Plymouth cases, while the Stockholm authors did
not perform a MA.
Figure 4. Meta-analysis of neonatal encephalopathy stage ≥2 according to Sarnat & Sarnat (29). The Sarnat & Sarnat classification was used only
in the Swedish (Amer-Wahlin et al., 2001) and Dutch (Westerhuis et al., 2010) trials (8,11).
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The European consortium MA authors inexplicably
excluded the Finnish RCT mortality data. However, in
the IPD MA, also performed by the European consor-
tium, the Finnish data were included. In the IPD MA the
Swedish RCT was represented by mortality corrected for
lethal malformations but the Dutch RCT was represented
by uncorrected mortality figures. These discrepancies raise
concern about the interpretation of data on perinatal
mortality.
Conclusions
To perform an MA, the included RCTs should address the
same research question, be of comparable quality regarding
selection bias, attrition rates and confounding variables,
and include comparable populations (16). As discussed in
the accompanying Part I review (6), there were consider-
able discrepancies in these aspects among the five RCTs.
Furthermore, numerous errors appear to have occurred in
the MAs, either created de novo in handling of the original
or imputed data or through a failure to recognize some
critical differences in data presentations in the RCTs. Met-
abolic acidosis, an essential perinatal outcome parameter,
was presented as a mixture of BDblood and BDecf data in
the Cochrane, American and Stockholm MAs.
None of the five MAs contained complete and relevant
data from all of the five RCTs. The decisions of the
authors of the various MAs to include some or all of the
RCT data in their analyses differed considerably. While
the RCTs included in the MAs clearly differed in inclu-
sion criteria, a question central to any MA is whether the
system being studied was used as intended and was
labelled by its manufacturer. With this in mind, we are of
the opinion that the French RCT should have been
excluded, since initiating ST monitoring in fetuses with
clearly abnormal CTGs is contrary to existing guidelines.
Conversely, the exclusion of the Plymouth RCT on the
basis of its older technology would appear unwarranted,
as this RCT, using manual rather than automated ST
analysis, would to an even greater extent have challenged
the ability of the CTG+ST analysis system to improve
perinatal outcomes.
It is unfortunate that the IPD MA, with its potential
clinical and statistical advantages over the aggregate MAs,
was found to have several errors. This could have led to
unintended bias in both the experimental and control
groups. For the outcomes of FBS, operative delivery,
ODFD, neonatal metabolic acidosis and neonatal Sarnat
& Sarnat encephalopathy stage ≥2, we have performed
new MAs. These showed not only, like the previous MAs,
a significant reduction in FBS usage in the CTG+ST
group (reduction of 36%), but also significant reductions
in total operative delivery rate (reduction of 7%) and in
neonatal metabolic acidosis rate (reduction of 39%). The
results of the ongoing multicenter RCT in the United
States (http://clinicaltrials.gov/ct2/show/NCT01131260)
are some months away. Certainly the contribution of the
USA data will help to determine whether the addition of
ST analysis to conventional CTG results in improved
perinatal outcomes.
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